WHAT IS CLAIMED IS:

1. An isolated polynucleotide comprising

a. a sequence selected from the group consisting of: SEQ ID NO:5, SEQ ID NO.: 6 and SEQ ID NO:7; and

b. a sequence selected from the group consisting of:SEQ ID NO: 21, SEQ ID NO: 22 and SEQ ID NO:23; and

c. sequence ID NO:24.

2. An isolated polynucleotide comprising SEQ ID NO.:8, SEQ ID NO.: 9 and SEQ ID NO.:10.

3. An isolated polynucleotide according to claim 1 or claim 2, which encodes a fusion polypeptide.

4. An isolated polynucleotide comprising SEQ ID No.:3.

5. An isolated polynucleotide comprising SEQ ID No.:4.

6. An isolated polynucleotide according to claim 4 or 5, wherein said isolated polynucleotide encodes a fusion polypeptide.

7. An isolated polynucleotide comprising a sequence having at least 80% identity to SEQ ID NO:3, wherein said isolated polynucleotide encodes a fusion polypeptide.

8. An isolated polynucleotide comprising a sequence having at least 80% identity to SEQ ID NO:4, wherein said isolated polynucleotide encodes a fusion polypeptide.

9. An isolated polynucleotide comprising

a. a sequence encoding a polypeptide having the sequence of SEQ ID No.:1; and

b. a sequence encoding a polypeptide having the sequence of an antibody Fc region, or a fragment thereof, from a species other than mouse.

10. An isolated polynucleotide comprising

a. a sequence encoding a polypeptide having the sequence of SEQ ID No.:2; and

b. a sequence encoding a polypeptide having the sequence of an antibody Fc region, or a fragment thereof, from a species other than mouse.

11. An isolated polynucleotide encoding a polypeptide having the sequence of SEQ ID No.:1.

12. An isolated polynucleotide encoding a polypeptide having the sequence of SEQ ID No.:2.

13. An isolated polynucleotide comprising SEQ ID NO.: 11.

14. An isolated polynucleotide comprising SEQ ID NO.: 12.

15. An isolated polynucleotide comprising a sequence having at least 80% identity to SEQ ID NO.:11 or to SEQ ID NO.:12.

16. An isolated polynucleotide comprising a sequence having at least 85% identity to SEQ ID NO.:11 or to SEQ ID NO.:12.

17. An isolated polynucleotide comprising a sequence having at least 90% identity to SEQ ID NO.:11 or to SEQ ID NO.:12.

18. An isolated polynucleotide comprising a sequence having at least 95% identity to SEQ ID NO.:11 or to SEQ ID NO.:12.

19. An isolated polynucleotide comprising a sequence having at least 99% identity to SEQ ID NO.:11 or to SEQ ID NO.:12.

20. An isolated polynucleotide comprising a sequence that encodes a polypeptide having SEQ ID NO:13 (heavy chain aa).

21. An isolated polynucleotide comprising a sequence that encodes a polypeptide having SEQ ID NO:14 (light chain aa).

22. An isolated polynucleotide comprising

a. a sequence encoding a polypeptide having the V_H region of the murine B-Ly1 antibody, or variants thereof; and

b. a sequence encoding a polypeptide having the sequence of an antibody Fc region, or a fragment thereof, from a species other than mouse.

23. An isolated polynucleotide comprising

a. a sequence encoding a polypeptide having the V_L region of the murine B-Ly1 antibody, or variants thereof; and

b. a sequence encoding a polypeptide having the sequence of an antibody Fc region, or a fragment thereof, from a species other than mouse.

24. An expression vector comprising an isolated polynucleotide according to any one of claims 1-23.

25. The vector of claim 24, wherein said vector is polycistronic.

26. A host cell comprising the expression vector of claim 24.

27. A host cell comprising an isolated polynucleotide according to any one of claims 1-23.

28. A polypeptide comprising a sequence derived from the murine B-Ly1 antibody and a sequence derived from a heterologous polypeptide.

29. An antigen-binding molecule comprising the polypeptide of claim 28.

30. An antigen-binding molecule according to claim 29, which binds human CD20.

31. An antigen-binding molecule according to claim 29, which is an antibody.

32. An antigen-binding molecule according to claim 31, which is a chimeric antibody.

33. An antigen-binding molecule according to claim 31, which is a humanized antibody.

34. An antigen-binding molecule according to claim 31, which is a primatized antibody.

35. A chimeric polypeptide comprising the sequence of SEQ ID NO:1 or a variant thereof.

36. A chimeric polypeptide comprising the sequence of SEQ ID NO:2 or a variant thereof.

37. A chimeric polypeptide comprising:

a. a polypeptide having a sequence selected from the group consisting of: SEQ ID NO:15, SEQ ID NO:16 and SEQ ID NO: 17; and

b. a polypeptide having a sequence selected from the group consisting of: SEQ ID NO:25, SEQ ID NO:26 and SEQ ID NO: 27; and

c. SEQ ID NO:28.

38. A chimeric polypeptide according to claim 37, further comprising a heavy chain variable region framework, wherein said framework comprises an alanine residue at position 71, according to Kabat numbering.

39. A chimeric polypeptide according to claim 37, further comprising a heavy chain variable region framework, wherein said framework comprises an arginine residue at position 94, according to Kabat numbering.

40. A chimeric polypeptide comprising SEQ ID NO:18, SEQ ID NO:19 and SEQ ID NO: 20.

41. An isolated polypeptide comprising SEQ ID NO:13 or a variant thereof.

42. An isolated polypeptide comprising SEQ ID NO:14 or a variant therof.

43. The isolated polypeptide according to any of claims 35-40, wherein said polypeptide is a fusion polypeptide.

44. An antigen binding molecule comprising the isolated polypeptide of claim 43.

45. The antigen binding molecule of claim 44, wherein said antigen binding molecule is an antibody.

46. The antibody of claim 45, wherein said antibody is a primatized antibody.

47. The antibody of claim 45, wherein said antibody is a humanized antibody.

48. The antigen binding molecule of claim 44, wherein said antigen binding molecule is an antibody fragment.

49. The antibody fragment of claim 48, wherein said antibody fragment is primatized.

50. The antigen binding molecule of claim 48, wherein said antibody fragment is humanized.

51. An antigen binding molecule, which is capable of competing with the murine B-Ly1 antibody for binding to CD20, wherein said antigen binding molecule is chimeric.

52. The antigen binding molecule of claim 51, wherein said antigen binding molecule is an antibody.

53. The antigen binding molecule of claim 52, wherein said antibody is primatized.

54. The antigen binding molecule of claim 51, wherein said recombinant antibody is humanized.

55. The antigen binding molecule of claim 51, wherein said recombinant antibody comprises a human Fc region.

56. The antigen binding molecule of claim 55, wherein said human Fc region is a human IgG Fc region.

57. An antigen binding molecule of any of claims 29-34 or 44-56, said antigen binding molecule having an Fc region with modified oligosaccharides.

58. An antigen binding molecule according to claim 57, wherein said Fc region has been modified to have reduced fucose residues as compared to non-modified antigen binding molecule.

59. An antigen binding molecule according to claim 57, wherein said Fc region has an increased proportion of bisected oligosaccharides.

60. An antigen binding molecule according to claim 59, wherein said modified oligosaccharides are bisected complex.

61. An antigen binding molecule according to claim 57, wherein said modified oligosaccharides have an increased proportion of bisected, nonfucosylated oligosaccharides in the Fc region of said antigen binding molecule.

62. An antigen binding molecule according to claim 61, wherein said bisected, nonfucosylated oligosaccharides are hybrid.

63. An antigen binding molecule according to claim 61, wherein said bisected, nonfucosylated oligosaccharides are complex.

64. An antigen binding molecule according to claim 57, wherein at least 20% of the oligosacchardies in the Fc region of said polypeptide are bisected, nonfucosylated.

65. An antigen binding molecule according to claim 57, wherein at least 30% of the oligosacchardies in the Fc region of said polypeptide are bisected, nonfucosylated.

66. An antigen binding molecule according to claim 57, wherein at least 35% of the oligosacchardies in the Fc region of said polypeptide are bisected, nonfucosylated.

67. An antigen binding molecule according to claim 57, wherein at least 70% of the oligosacchardies in the Fc region of said polypeptide are bisected, nonfucosylated.

68. A method of producing an antigen binding molecule, which is capable of competing with the murine B-Ly1 antibody for binding to human CD20, and wherein said antigen binding molecule is chimeric; said method comprising

a. culturing the host cell of claim 26 or claim 27 in a medium under conditions allowing the expression of said polynucleotide encoding said antigen binding molecule; and

b. recovering said antigen binding molecule from the resultant culture.

69. The method of claim 68, wherein said antigen binding molecule is an antibody.

70. A pharmaceutical composition comprising the antigen binding molecule according to any of claims 29-34 or 46-67 and a pharmaceutically acceptable carrier.

71. The pharmaceutical composition of claim 70, wherein said composition further comprises a pharmaceutically acceptable carrier.

72. The pharmaceutical composition of claim 70, wherein said composition further comprises an adjuvant.

73. Use of a pharmaceutical composition of any of claims 70-72 in the manufacture of a medicament for treating a disorder treatable by B-cell depletion in a human subject in need thereof.

74. A host cell engineered to express at least one nucleic acid encoding a polypeptide having β(1,4)-N-acetylglucosaminyltransferase III activity in an

amount sufficient to modify the oligosaccharides in the Fc region of a polypeptide produced by said host cell, wherein said polypeptide is an antigen binding molecule according to any of claims 44-67.

75. The host cell of claim 74, wherein said polypeptide having β(1,4)-N-acetylglucosaminyltransferase III activity is a fusion polypeptide.

76. The host cell of claim 74, wherein said antigen binding molecule is an antibody.

77. The host cell of claim 74, wherein said antigen binding molecule is an antibody fragment.

78. The host cell of claim 74, wherein said antigen binding molecule comprises a region equivalent to the Fc region of a human IgG.

79. The host cell of claim 74, wherein said antigen binding molecule produced by said host cell exhibits increased Fc receptor binding affinity as a result of said modification.

80. The host cell of claim 74, wherein said antigen binding molecule produced by said host cell exhibits increased effector function as a result of said modification.

81. A host cell according to claim 75, wherein said fusion polypeptide comprises the catalytic domain of β(1,4)-N-acetylglucosaminyltransferase III.

82. A host cell according to claim 75, wherein said fusion polypeptide further comprises the Golgi localization domain of a heterologous Golgi resident polypeptide.

83. A host cell according to claim 82, wherein said Golgi localization domain is the localization domain of mannosidase II.

84. A host cell according to claim 82, wherein said Golgi localization domain is the localization domain of β(1,2)-N-acetylglucosaminyltransferase I.

85. A host cell according to claim 82, wherein said Golgi localization domain is the localization domain of β(1,2)-N-acetylglucosaminyltransferase II.

86. A host cell according to claim 82, wherein said Golgi localization domain is the localization domain of mannosidase I.

87. A host cell according to claim 82, wherein said Golgi localization domain is the localization domain of α1-6 core fucosyltransferase.

88. A host cell according to claim 80, wherein said increased effector function is increased Fc-mediated cellular cytotoxicity.

89. A host cell according to claim 80, wherein said increased effector function is increased binding to NK cells.

90. A host cell according to claim 80, wherein said increased effector function is increased binding to macrophages.

91. A host cell according to claim 80, wherein said increased effector function is increased binding to polymorphonuclear cells.

92. A host cell according to claim 80, wherein said increased effector function is increased binding to monocytes.

93. A host cell according to claim 80, wherein said increased effector function is increased direct signaling inducing apoptosis.

94. A host cell according to claim 80, wherein said increased effector function is increased dendritic cell maturation.

95. A host cell according to claim 80, wherein said increased effector function is increased T cell priming.

96. A host cell according to claim 79, wherein said Fc receptor is Fcγ activating receptor.

97. A host cell according to claim 79, wherein said Fc receptor is FcγRIIIA receptor.

98. A host cell according to claim 74, wherein said host cell is a CHO cell, a BHK cell, a NSO cell, a SP2/0 cell, a YO myeloma cell, a P3X63 mouse myeloma cell, a PER cell, a PER.C6 cell or a hybridoma cell.

99. The host cell of claim 74, further comprising at least one transfected polynucleotide encoding a polypeptide according to any of claims 28 and 35-41, and wherein said nucleic acid comprises a sequence encoding a region equivalent to the Fc region of a human immunoglobulin.

100. The host cell of claim 74, wherein said at least one nucleic acid encoding a polypeptide having β(1,4)-N-acetylglucosaminyltransferase III activity is operably linked to a constitutive promoter element.

101. The host cell of claim 100, wherein said polypeptide having β(1,4)-N-acetylglucosaminyltransferase III activity is a fusion polypeptide.

102. A method for producing an antigen binding molecule having modified oligosaccharides in a host cell, said method comprising:

a. culturing a host cell engineered to express at least one nucleic acid encoding a polypeptide having β(1,4)-N-acetylglucosaminyltransferase III activity under conditions which permit the production of said antigen binding molecule, and which permit the modification of the oligosaccharides present on the Fc region of said antigen binding molecule; and

b. isolating said antigen binding molecule wherein said antigen binding molecule is capable of competing with the murine B-Ly1 antibody for binding to CD20 and wherein said antigen binding molecule or fragment thereof is chimeric.

103. A method according to claim 102, wherein said modified oligosaccharides have reduced fucosylation as compared to non-modified oligosaccharides.

104. A method according to claim 102, wherein said modified oligosaccharides are hybrid.

105. A method according to claim 102, wherein said modified oligosaccharides are complex.

106. A method according to claim 102, wherein said recombinant antibody or fragment thereof produced by said host cell has an increased proportion of bisected, nonfucosylated oligosaccharides in the Fc region of said polypeptide.

107. A method according to claim 106, wherein said bisected, nonfucosylated oligosaccharides are hybrid.

108. A method according to claim 106, wherein said bisected, nonfucosylated oligosaccharides are complex.

109. A method according to claim 102, wherein at least 20% of the oligosaccharides in the Fc region of said polypeptide are bisected, nonfucosylated.

110. A method according to claim 102, wherein at least 30% of the oligosaccharides in the Fc region of said polypeptide are bisected, nonfucosylated.

111. A method according to claim 102, wherein at least 35% of the oligosaccharides in the Fc region of said polypeptide are bisected, nonfucosylated.

112. An antigen binding molecule engineered to have increased effector function produced by the method according to any one of claims 102-111.

113. The antigen binding molecule of claim 112, wherein said antigen binding molecule is an antibody

114. An antibody engineered to have increased Fc receptor binding affinity produced by the method of any one of claims 102-111.

115. The antigen binding molecule of claim 114, wherein said antigen binding molecule is an antibody.

116. An antigen binding molecule according to claim 112, wherein said increased effector function is increased Fc-mediated cellular cytotoxicity.

117. An antigen binding molecule according to claim 112, wherein said increased effector function is increased binding to NK cells.

118. An antigen binding molecule according to claim 112, wherein said increased effector function is increased binding to macrophages.

119. An antigen binding molecule according to claim 112, wherein said increased effector function is increased binding to monocytes.

120. An antigen binding molecule according to claim 112, wherein said increased effector function is increased binding to polymorphonuclear cells.

121. An antigen binding molecule according to claim 112, wherein said increased effector function is direct signaling inducing apoptosis.

122. An antigen binding molecule according to claim 112, wherein said increased effector function is increased dendritic cell maturation.

123. An antigen binding molecule according to claim 112, wherein said increased effector function is increased T cell priming.

124. An antigen binding molecule according to claim 114, wherein said Fc receptor is Fc activating receptor.

125. An antigen binding molecule according to claim 114, wherein said Fc receptor is FcγRIIIa receptor.

126. An antigen binding molecule produced by the method of any of claims 102 to 111, wherein said antigen binding molecule is an antibody fragment containing the Fc region and engineered to have increased effector function.

127. An antigen binding molecule produced by the method of any of claims 102 to 111, wherein said antigen binding molecule is a fusion protein that includes a polypeptide having the sequence of SEQ ID NO:1 and a region equivalent to the Fc region of an immunoglobulin and engineered to have increased effector function.

128. An antigen binding molecule produced by the method of any of claims 102 to 111, wherein said antigen binding molecule is a fusion protein that includes a polypeptide having a sequence selected from the group consisting of ~~SEQ ID No:30; SEQ ID No:32; SEQ ID No:34; SEQ ID No:36; SEQ ID No:38;~~

SEQ ID No:40; SEQ ID No:42; SEQ ID No:44; SEQ ID No:46; SEQ ID No:48; SEQ ID No:50; SEQ ID No:52; SEQ ID No:54; SEQ ID No:56; SEQ ID No:58; SEQ ID No:60; SEQ ID No:62; SEQ ID No:64; SEQ ID No:66; SEQ ID No:68; SEQ ID No:70; and SEQ ID No:72, and a region equivalent to the Fc region of an immunoglobulin and engineered to have increased effector function.

129. An antigen binding molecule produced by the method of any of claims 102 to 111, wherein said antigen binding molecule is a fusion protein that includes a polypeptide having the sequence of SEQ ID NO:3 and a region equivalent to the Fc region of an immunoglobulin and engineered to have increased effector function.

130. An antigen binding molecule produced by the method of any of claims 102 to 111, wherein said antigen binding molecule is a fusion protein that includes a polypeptide having the sequence of SEQ ID NO:76 and a region equivalent to the Fc region of an immunoglobulin and engineered to have increased effector function.

131. A pharmaceutical composition comprising the antigen binding molecule of any of claims 112 to 130 and a pharmaceutically acceptable carrier.

132. A pharmaceutical composition comprising the antibody fragment of claim 126 and a pharmaceutically acceptable carrier.

133. A pharmaceutical composition comprising the fusion protein of any of claims 127 to 130 and a pharmaceutically acceptable carrier.

134. Use of the antigen binding according to any of claims 112 to 130 in the manufacture of a medicament for treating a disease treatable by B-cell depletion in a human subject in need thereof.

135. An isolated polynucleotide according to claim 4 or 5 further comprising a sequence encoding a human antibody light or heavy chain constant region.

136. An isolated polynucleotide comprising a sequence with at least 80% identity to SEQ ID NO:24, wherein said isolated polynucleotide encodes a fusion polypeptide.

137. A host cell coexpressing an isolated polynucleotide according to claim 136 and a polynucleotide comprising a sequence encoding the variable region of an antibody light chain.

138. An antigen binding molecule according to claim 57, wherein at least 50% of the oligosaccharides in the Fc region are bisected.

139. An antigen binding molecule according to claim 57, wherein at least 60% of the oligosaccharides in the Fc region are bisected.

140. An antigen binding molecule according to claim 57, wherein at least 70% of the oligosaccharides in the Fc region are bisected.

141. An antigen binding molecule according to claim 57, wherein at least 80% of the oligosaccharides in the Fc region are bisected.

142. An antigen binding molecule according to claim 57, wherein at least 90% of the oligosaccharides in the Fc region are bisected.

143. An antigen binding molecule according to claim 57, wherein at least 50% of the oligosaccharides in the Fc region are nonfucosylated.

144. An antigen binding molecule according to claim 57, wherein at least 60% of the oligosaccharides in the Fc region are nonfucosylated.

145. An antigen binding molecule according to claim 57, wherein at least 70% of the oligosaccharides in the Fc region are nonfucosylated.

146. An antigen binding molecule according to claim 57, wherein at least 75% of the oligosaccharides in the Fc region are nonfucosylated.

147. A method according to claim 73, wherein said disorder is a B cell lymphoma.

148. An isolated polynucleotide comprising a sequence selected from the group consisting of SEQ ID No:29; SEQ ID No:31; SEQ ID No:33; SEQ ID No:35; SEQ ID No:37; SEQ ID No:39; SEQ ID No:41; SEQ ID No:43; SEQ ID No:45; SEQ ID No:47; SEQ ID No:49; SEQ ID No:51; SEQ ID No:53; SEQ ID No:55; SEQ ID No:57; SEQ ID No:59; SEQ ID No:61; SEQ ID No:63; SEQ ID No:65; SEQ ID No:67; SEQ ID No:69; and SEQ ID No:71.

149. An isolated polynucleotide according to claim 148, wherein said isolated polynucleotide comprises SEQ ID NO:31.

150. An isolated polynucleotide according to claim 148, wherein said isolated polynucleotide comprises SEQ ID NO:55.

151. An isolated polynucleotide according to claim 148, wherein said isolated polynucleotide comprises SEQ ID NO:59.

152. An isolated polynucleotide comprising SEQ ID No:75.

153. An isolated polynucleotide according to claim 148 or 149, wherein said isolated polynucleotide encodes a fusion polypeptide.

154. An isolated polynucleotide comprising

a) a sequence encoding a polypeptide having a sequence selected from the group consisting of SEQ ID NO:32; SEQ ID NO:56; and SEQ ID NO:60; and

b) a sequence encoding a polypeptide having the sequence of SEQ ID NO:76

155. An isolated polynucleotide comprising a sequence having at least 80% identity to a sequence selected from the group consisting of SEQ ID No:29; SEQ ID No:31; SEQ ID No:33; SEQ ID No:35; SEQ ID No:37; SEQ ID No:39; SEQ ID No:41; SEQ ID No:43; SEQ ID No:45; SEQ ID No:47; SEQ ID No:49; SEQ ID No:51; SEQ ID No:53; SEQ ID No:55; SEQ ID No:57; SEQ ID No:59; SEQ ID No:61; SEQ ID No:63; SEQ ID No:65; SEQ ID No:67; SEQ ID No:69; and SEQ ID No:71, wherein said isolated polynucleotide encodes a fusion polypeptide.

156. An isolated polynucleotide comprising a sequence having at least 80% identity to SEQ ID NO:75, wherein said isolated polynucleotide encodes a fusion polypeptide.

157. An isolated polynucleotide comprising a sequence having at least 85% identity to a sequence selected from the group consisting of SEQ ID No:29; SEQ ID No:31; SEQ ID No:33; SEQ ID No:35; SEQ ID No:37; SEQ ID No:39; SEQ ID No:41; SEQ ID No:43; SEQ ID No:45; SEQ ID No:47; SEQ ID No:49; SEQ ID No:51; SEQ ID No:53; SEQ ID No:55; SEQ ID No:57; SEQ ID No:59; SEQ ID No:61; SEQ ID No:63; SEQ ID No:65; SEQ ID No:67; SEQ ID No:69; and SEQ ID No:71.

158. An isolated polynucleotide comprising a sequence having at least 85% identity to SEQ ID No: 75.

159. An isolated polynucleotide comprising a sequence having at least 90% identity to a sequence selected from the group consisting of SEQ ID No:29; SEQ ID No:31; SEQ ID No:33; SEQ ID No:35; SEQ ID No:37; SEQ ID No:39; SEQ ID No:41; SEQ ID No:43; SEQ ID No:45; SEQ ID No:47; SEQ ID No:49; SEQ ID No:51; SEQ ID No:53; SEQ ID No:55; SEQ ID No:57; SEQ ID No:59; SEQ ID No:61; SEQ ID No:63; SEQ ID No:65; SEQ ID No:67; SEQ ID No:69; and SEQ ID No:71.

160. An isolated polynucleotide comprising a sequence having at least 90% identity to SEQ ID No: 75.

161. An isolated polynucleotide comprising a sequence having at least 95% identity to a sequence selected from the group consisting of SEQ ID No:29; SEQ ID No:31; SEQ ID No:33; SEQ ID No:35; SEQ ID No:37; SEQ ID No:39; SEQ ID No:41; SEQ ID No:43; SEQ ID No:45; SEQ ID No:47; SEQ ID No:49; SEQ ID No:51; SEQ ID No:53; SEQ ID No:55; SEQ ID No:57; SEQ ID No:59; SEQ ID No:61; SEQ ID No:63; SEQ ID No:65; SEQ ID No:67; SEQ ID No:69; and SEQ ID No:71.

162. An isolated polynucleotide comprising a sequence having at least 95% identity to SEQ ID No: 75.

163. An isolated polynucleotide comprising a sequence having at least 99% identity to a sequence selected from the group consisting of SEQ ID No:29; SEQ ID No:31; SEQ ID No:33; SEQ ID No:35; SEQ ID No:37; SEQ ID No:39; SEQ ID No:41; SEQ ID No:43; SEQ ID No:45; SEQ ID No:47; SEQ ID No:49; SEQ ID No:51; SEQ ID No:53; SEQ ID No:55; SEQ ID No:57; SEQ ID No:59; SEQ ID No:61; SEQ ID No:63; SEQ ID No:65; SEQ ID No:67; SEQ ID No:69; and SEQ ID No:71.

164. An isolated polynucleotide comprising a sequence having at least 99% identity to SEQ ID No: 75.

165. An isolated polynucleotide comprising

a) a sequence encoding a polypeptide having a sequence selected from the group consisting of SEQ ID No:30; SEQ ID No:32; SEQ ID No:34; SEQ ID No:36; SEQ ID No:38; SEQ ID No:40; SEQ ID No:42; SEQ ID No:44; SEQ ID No:46; SEQ ID No:48; SEQ ID No:50; SEQ ID No:52; SEQ ID No:54; SEQ ID No:56; SEQ ID No:58; SEQ ID No:60; SEQ ID No:62; SEQ ID No:64; SEQ ID No:66; SEQ ID No:68; SEQ ID No:70; and SEQ ID No:72; and

b) a sequence encoding a polypeptide having the sequence of an antibody Fc region, or a fragment thereof, from a species other than mouse.

166. An isolated polynucleotide comprising

a) a sequence encoding a polypeptide having the sequence of SEQ ID No:76; and

b) a sequence encoding a polypeptide having the sequence of an antibody Fc region, or a fragment thereof, from a species other than mouse.

167. An isolated polynucleotide encoding a polypeptide having a sequence selected from the group consisting of SEQ ID No:30; SEQ ID No:32; SEQ ID No:34; SEQ ID No:36; SEQ ID No:38; SEQ ID No:40; SEQ ID No:42; SEQ ID No:44; SEQ ID No:46; SEQ ID No:48; SEQ ID No:50; SEQ ID No:52; SEQ ID No:54; SEQ ID No:56; SEQ ID No:58; SEQ ID No:60; SEQ ID No:62; SEQ ID No:64; SEQ ID No:66; SEQ ID No:68; SEQ ID No:70; and SEQ ID No:72.

168. An isolated polynucleotide encoding a polypeptide having the sequence of SEQ ID No:76.

169. An isolated polynucleotide comprising a sequence that encodes a polypeptide having a sequence selected from the group consisting of SEQ ID No:30; SEQ ID No:32; SEQ ID No:34; SEQ ID No:36; SEQ ID No:38; SEQ ID No:40; SEQ ID No:42; SEQ ID No:44; SEQ ID No:46; SEQ ID No:48; SEQ ID No:50; SEQ ID No:52; SEQ ID No:54; SEQ ID No:56; SEQ ID No:58; SEQ ID No:60; SEQ ID No:62; SEQ ID No:64; SEQ ID No:66; SEQ ID No:68; SEQ ID No:70; and SEQ ID No:72.

170. An isolated polynucleotide comprising a sequence that encodes a polypeptide having SEQ ID NO:76.

171. An expression vector comprising an isolated polynucleotide according to any one of claims 148-170.

~~172. The vector of claim 171, wherein said vector is polycistronic.~~

173. A host cell comprising the expression vector of claim 171.

174. A host cell comprising an isolated polynucleotide according to any one of claims 148-170.

175. A humanized polypeptide comprising a sequence selected from the group consisting of SEQ ID No:30; SEQ ID No:32; SEQ ID No:34; SEQ ID No:36; SEQ ID No:38; SEQ ID No:40; SEQ ID No:42; SEQ ID No:44; SEQ ID No:46; SEQ ID No:48; SEQ ID No:50; SEQ ID No:52; SEQ ID No:54; SEQ ID No:56; SEQ ID No:58; SEQ ID No:60; SEQ ID No:62; SEQ ID No:64; SEQ ID No:66; SEQ ID No:68; SEQ ID No:70; and SEQ ID No:72, or a variant thereof.

176. A humanized polypeptide comprising the sequence of SEQ ID NO:76, or a variant thereof.

177. An isolated polypeptide comprising a sequence selected from the group consisting of SEQ ID No:30; SEQ ID No:32; SEQ ID No:34; SEQ ID No:36; SEQ ID No:38; SEQ ID No:40; SEQ ID No:42; SEQ ID No:44; SEQ ID No:46; SEQ ID No:48; SEQ ID No:50; SEQ ID No:52; SEQ ID No:54; SEQ ID No:56; SEQ ID No:58; SEQ ID No:60; SEQ ID No:62; SEQ ID No:64; SEQ ID No:66; SEQ ID No:68; SEQ ID No:70; and SEQ ID No:72, or a variant thereof.

178. An isolated polypeptide comprising SEQ ID NO:76, or a variant thereof.

179. The isolated polypeptide according to any of claims 177-178, wherein said polypeptide is a fusion polypeptide.

180. An antigen binding molecule comprising the isolated polypeptide of claim 179.

181. The antigen binding molecule of claim 180, wherein said antigen binding molecule is an antibody.

182. The antibody of claim 181, wherein said antibody is a humanized antibody.

183. The antigen binding molecule of claim 180, wherein said antigen binding molecule is an antibody fragment.

184. The antigen binding molecule of claim 183, wherein said antibody fragment is humanized.

185. The antigen binding molecule of claim 180, wherein said antigen binding molecule is a recombinant antibody.

186. The antigen binding molecule of claim 185, wherein said recombinant antibody is humanized.

187. The antigen binding molecule of claim 180, wherein said recombinant antibody comprises a human Fc region.

188. The antigen binding molecule of claim 187, wherein said human Fc region is a human IgG Fc region.

189. An antigen binding molecule of any of claims 180-188, said antigen binding molecule having an Fc region with modified oligosaccharides.

190. An antigen binding molecule according to claim 189, wherein said Fc region has been modified to have reduced fucose residues as compared to non-modified antigen binding molecule.

191. An antigen binding molecule according to claim 189, wherein said Fc region has an increased proportion of bisected oligosaccharides.

192. An antigen binding molecule according to claim 189, wherein said modified oligosaccharides are bisected complex.

193. An antigen binding molecule according to claim 189, wherein said modified oligosaccharides have an increased proportion of bisected, nonfucosylated oligosaccharides in the Fc region of said antigen binding molecule.

194. An antigen binding molecule according to claim 193, wherein said bisected, nonfucosylated oligosaccharides are hybrid.

195. An antigen binding molecule according to claim 193, wherein said bisected, nonfucosylated oligosaccharides are complex.

196. An antigen binding molecule according to claim 189, wherein at least 20% of the oligosacchardies in the Fc region of said polypeptide are bisected, nonfucosylated.

197. An antigen binding molecule according to claim 189, wherein at least 30% of the oligosacchardies in the Fc region of said polypeptide are bisected, nonfucosylated.

198. An antigen binding molecule according to claim 189, wherein at least 35% of the oligosacchardies in the Fc region of said polypeptide are bisected, nonfucosylated.

199. An antigen binding molecule according to claim 189, wherein at least 70% of the oligosaccharides in the Fc region of said polypeptide are bisected, nonfucosylated.

200. A method of producing an antigen binding molecule, which is capable of competing with the murine B-Ly1 antibody for binding to human CD20, and wherein said antigen binding molecule is chimeric; said method comprising

a) culturing the host cell of claim 173 or claim 174 in a medium under conditions allowing the expression of said polynucleotide encoding said antigen binding molecule; and

b) recovering said antigen binding molecule.

201. The method of claim 200, wherein said antigen binding molecule is an antibody.

202. The method of claim 200, wherein said chimeric antigen binding molecule is humanized.

203. A pharmaceutical composition comprising the antigen binding molecule according to any of claims 189-199 and a pharmaceutically acceptable carrier.

204. The pharmaceutical composition of claim 203, wherein said composition further comprises a pharmaceutically acceptable carrier.

205. The pharmaceutical composition of claim 203, wherein said composition further comprises an adjuvant.

206. Use of pharmaceutical composition of any of claims 203-205 in the manufacture of a medicament for treating a disorder treatable by B-cell depletion in a human subject in need thereof.

207. A host cell engineered to express at least one nucleic acid encoding a polypeptide having β(1,4)-N-acetylglucosaminyltransferase III activity in an amount sufficient to modify the oligosaccharides in the Fc region of a polypeptide produced by said host cell, wherein said polypeptide is an antigen binding molecule according to any of claims 180-197.

208. The host cell of claim 207, wherein said polypeptide having β(1,4)-N-acetylglucosaminyltransferase III activity is a fusion polypeptide.

209. The host cell of claim 207, wherein said antigen binding molecule is an antibody.

210. The host cell of claim 207, wherein said antigen binding molecule is an antibody fragment.

211. The host cell of claim 207, wherein said antigen binding molecule comprises a region equivalent to the Fc region of a human IgG.

212. The host cell of claim 207, wherein said antigen binding molecule produced by said host cell exhibits increased Fc receptor binding affinity as a result of said modification.

213. The host cell of claim 207, wherein said antigen binding molecule produced by said host cell exhibits increased effector function as a result of said modification.

214. A host cell according to claim 208, wherein said fusion polypeptide ~~comprises the catalytic domain of β(1,4)-N-acetylglucosaminyltransferase III.~~

215. A host cell according to claim 208, wherein said fusion polypeptide further comprises the Golgi localization domain of a heterologous Golgi resident polypeptide.

216. A host cell according to claim 215, wherein said Golgi localization domain is the localization domain of mannosidase II.

217. A host cell according to claim 215, wherein said Golgi localization domain is the localization domain of β(1,2)-N-acetylglucosaminyltransferase I.

218. A host cell according to claim 215, wherein said Golgi localization domain is the localization domain of β(1,2)-N-acetylglucosaminyltransferase II.

219. A host cell according to claim 215, wherein said Golgi localization domain is the localization domain of mannosidase I.

220. A host cell according to claim 215, wherein said Golgi localization domain is the localization domain of α1-6 core fucosyltransferase.

221. A host cell according to claim 213, wherein said increased effector function is increased Fc-mediated cellular cytotoxicity.

222. A host cell according to claim 213, wherein said increased effector function is increased binding to NK cells.

223. A host cell according to claim 213, wherein said increased effector function is increased binding to macrophages.

224. A host cell according to claim 213, wherein said increased effector function is increased binding to polymorphonuclear cells.

225. A host cell according to claim 213, wherein said increased effector function is increased binding to monocytes.

226. A host cell according to claim 213, wherein said increased effector function is increased direct signaling inducing apoptosis.

227. A host cell according to claim 213, wherein said increased effector function is increased dendritic cell maturation.

228. A host cell according to claim 213, wherein said increased effector function is increased T cell priming.

229. A host cell according to claim 212, wherein said Fc receptor is Fcγ activating receptor.

230. A host cell according to claim 212, wherein said Fc receptor is FcγRIIIA receptor.

231. A host cell according to claim 207, wherein said host cell is a CHO cell, a BHK cell, a NSO cell, a SP2/0 cell, a YO myeloma cell, a P3X63 mouse myeloma cell, a PER cell, a PER.C6 cell or a hybridoma cell.

232. The host cell of claim 207, further comprising at least one transfected polynucleotide encoding a polypeptide according to any of claims 28 and 35-41, and wherein said nucleic acid comprises a sequence encoding a region equivalent to the Fc region of a human immunoglobulin.

233. The host cell of claim 207, wherein said at least one nucleic acid encoding a polypeptide having β(1,4)-N-acetylglucosaminyltransferase III activity is operably linked to a constitutive promoter element.

234. The host cell of claim 233, wherein said polypeptide having β(1,4)-N-acetylglucosaminyltransferase III activity is a fusion polypeptide.

235. An antigen binding molecule according to claim 189, wherein at least 50% of the oligosaccharides in the Fc region are bisected.

236. An antigen binding molecule according to claim 189, wherein at least 60% of the oligosaccharides in the Fc region are bisected.

237. An antigen binding molecule according to claim 189, wherein at least 70% of the oligosaccharides in the Fc region are bisected.

238. An antigen binding molecule according to claim 189, wherein at least 80% of the oligosaccharides in the Fc region are bisected.

239. An antigen binding molecule according to claim 189, wherein at least 90% of the oligosaccharides in the Fc region are bisected.

240. An antigen binding molecule according to claim 189, wherein at least 50% of the oligosaccharides in the Fc region are nonfucosylated.

241. An antigen binding molecule according to claim 189, wherein at least 60% of the oligosaccharides in the Fc region are nonfucosylated.

242. An antigen binding molecule according to claim 189, wherein at least 70% of the oligosaccharides in the Fc region are nonfucosylated.

243. An antigen binding molecule according to claim 189, wherein at least 75% of the oligosaccharides in the Fc region are nonfucosylated.

244. The use according to claim 206, wherein said disorder is a B cell lymphoma.

245. An isolated polynucleotide comprising at least one complementarity determining region of the murine B-Ly1 antibody, or a variant or truncated form thereof containing at least the specificity-determining residues for said complementarity determining region, wherein said isolated polynucleotide encodes a fusion polypeptide.

246. An isolated polynucleotide according to claim 245, wherein said complementarity determining region is selected from the group consisting of : [LIST ALL B-Ly1 CDR SEQUENCES].

247. An isolated polynucleotide according to claim 245, wherein said isolated polynucleotide encodes an antigen binding molecule.

248. An isolated polynucleotide comprising at least three complementarity determining regions of the murine B-Ly1 antibody, or variants or truncated forms thereof containing at least the specificity-determining residues for each of said three complementarity determining regions, wherein said isolated polynucleotide encodes a fusion polypeptide.

249. An isolated polynucleotide according to claim 248, wherein said complementarity determining regions comprise at least one sequence selected from the group consisting of : SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:7; and at least one sequence selected from the group consisting of: SEQ ID NO:21, SEQ ID NO:22, and SEQ ID NO:23; and SEQ ID NO:24, or variants or truncated forms of said sequences that contain at least the specificity-determining residues for each of said complementarity determining regions.

250. An isolated polypeptide encoded by the isolated polynucleotides of any of claims 245-249.

251. An antigen binding molecule comprising at least one complementarity determining region of the murine B-Ly1 antibody, or a variant or truncated form thereof containing at lest the specificity-determining residues for said

complementarity determining region, and further comprising a sequence derived from a heterologous polypeptide.

252. An antigen binding molecule according to claim 251, wherein said antigen binding molecule comprises at least three complementarity determining regions of the murine B-Ly1 antibody, or variants or truncated forms thereof containing at least the specificity-determining residues for each of said complementarity determining regions.

253. An antigen binding molecule according to claim 252, wherein said antigen binding molecule comprises the variable region of an antibody light or heavy chain.

254. An antigen binding molecule according to claim 252, wherein said antigen binding molecule is a chimeric or humanized, antibody.

255. An engineered Type II anti-CD20 antibody having increased ADCC as a result of said engineering without substantial loss of ability to induce apoptosis of target cells.

256. An engineered Type II anti-CD20 antibody according to claim 255, wherein said antibody has been engineered to have an altered pattern of glycosylation in the Fc region.

257. An engineered Type II anti-CD20 antibody according to claim 256, wherein said altered glycosylation is an increase in the amount of bisected complex oligosaccharides.

258. An engineered Type II anti-CD20 antibody according to claim 256, wherein said altered glycosylation is a decrease in the amount of fucose residues.

259. An engineered Type II anti-CD20 antibody according to claim 255, wherein said antibody has been engineered to have an altered amino acid sequence in the Fc region.

WHAT IS CLAIMED IS:

1. A humanized Type II anti-CD20 antigen binding molecule comprising:

(a) a heavy chain variable region selected from SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO. 42, SEQ ID NO:44, and SEQ ID NO:46; and

(b) the KVl light chain variable region of SEQ ID NO:76.

2. A humanized Type II anti-CD20 antigen binding molecule comprising:

(a) a heavy chain variable region selected from SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, and SEQ ID NO:72; and

(b) the KVl light chain variable region of SEQ ID NO:76.

3. A humanized Type-II anti-CD20 antigen binding molecule comprising a heavy chain variable region having the specificity determining residues of the heavy chain variable region of the antigen binding molecule of claim 1 or 2, wherein said antigen binding molecule induces higher level of apoptosis when incubated with CD20-positive human cells relative to a control under identical conditions using the C2B8 chimeric IgGl antibody with an identical sequence to rituximab.

4. An isolated polynucleotide encoding the heavy chain variable region of any one of claims 1 to 3.

5. An isolated polynucleotide encoding a heavy chain variable region having an amino acid sequence at least 80% identical to the heavy chain variable region of any one of claims 1 to 3.

6. A humanized Type-II anti-CD20 antigen binding molecule comprising the heavy chain variable region encoded by the nucleic acid sequence of claim 5 and the KV1 light chain variable region of SEQ ID NO: 76, wherein said antigen binding molecule induces higher level

of apoptosis when incubated with CD20-positive human cells relative to a control under identical conditions using the C2B8 chimeric IgG1 antibody with an identical sequence to rituximab.

7. An expression vector comprising the polynucleotide of claim 4 or 5.

8. An isolated host cell comprising the expression vector of claim 7.

9. A method for the production of the humanized Type-II anti-CD20 antigen binding molecule of any one of claims 1 to 3 and 6 comprising culturing the host cell of claim 8 under conditions that allow for the production of said antigen binding molecule and recovering said antigen binding molecule from said culture.

10. A humanized Type II anti-CD20 antigen binding molecule, wherein the antigen binding molecule is produced by the host cell of claim 8.

11. A pharmaceutical composition comprising the antigen binding molecule of any one of claims 1 to 3, 6 and 10, or produced by the method of claim 9, and a pharmaceutically acceptable carrier.

12. Use of the antigen binding molecule of any one of claims 1 to 3, 6 and 10, or produced by the method of claim 9, for the manufacture of a medicament to treat a B-cell disorder.

13. The use of claim 12, wherein said B-cell disorder is a B-cell lymphoma.

14. Use of the antigen binding molecule of any one of claims 1 to 3, 6 and 10, or produced by the method of claim 9, for the manufacture of a medicament to treat a

disorder treatable by B-cell depletion.

15. The use of claim 14, wherein said disorder is a haematological malignancy or an autoimmune disease.

16. The use of claim 15, wherein said haematological malignancy is B-cell lymphoma, non-Hodgkin's lymphoma, or B-cell chronic lymphocytic leukaemia.

17. The use of claim 15, wherein said autoimmune disease is rheumatoid arthritis or lupus.

18. The antigen binding molecule of any one of claims 1 to 3, 6 and 10, or produced by the method of claim 9, wherein said antigen binding molecule comprises a glycoengineered Fc region.

19. The antigen binding molecule of claim 18, wherein said antigen binding molecule has an increase in the fraction of non-fucosylated oligosaccharides attached to said glycoengineered Fc region.

20. The antigen binding molecule of claim 18, wherein said antigen binding molecule has an increase in the fraction of bisected, non-fucosylated oligosaccharides attached to said glycoengineered Fc region.

21. The antigen binding molecule of claim 18, wherein said antigen binding molecule has significantly higher levels of binding to human FcgammaRIII receptors relative to the non-glycoengineered antigen binding molecule.

22. The antigen binding molecule of claim 18, wherein said antigen binding

molecule has significantly higher levels of antibody-dependent cell-mediated cytotoxicity (ADCC) activity relative to the non-glycoengineered antigen binding molecule.